MET/HGF pathway activation as a paradigm of resistance to targeted therapies

Resistance to targeted therapeutics is a key issue limiting the long-term utility of these medications in the management of molecularly selected subsets of cancer patients, including patients with non-small cell lung cancer harboring oncogenic alterations affecting EGFR, ALK and other genes. Bypass...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Transl Med
Asıl Yazarlar: Ko, Brian, He, Tianfang, Gadgeel, Shirish, Halmos, Balazs
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: AME Publishing Company 2017
Konular:
Review Article on MET as Actionable Target in Cancer Therapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5253284/
https://ncbi.nlm.nih.gov/pubmed/28164089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm.2016.12.09
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller